Sara Nasser

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

This study compares tumor cell phenotype and heterogeneity differences between IDH1 mutant and wild-type gliomas using integrated multi-omics data.